KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for Regeneron Pharmaceuticals (REGN) over the last 10 years, with Dec 2024 value amounting to $2.5 billion.

  • Regeneron Pharmaceuticals' Accumulated Expenses rose 17.32% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 17.32%. This contributed to the annual value of $2.5 billion for FY2024, which is 7.18% up from last year.
  • Regeneron Pharmaceuticals' Accumulated Expenses amounted to $2.5 billion in FY2024, which was up 7.18% from $2.4 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Accumulated Expenses registered a high of $2.5 billion during FY2024, and its lowest value of $1.6 billion during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $2.4 billion (2023), whereas its average is $2.3 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Accumulated Expenses soared by 35.73% in 2020, and later dropped by 6.01% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Accumulated Expenses (Yearly) stood at $1.6 billion in 2020, then spiked by 34.22% to $2.2 billion in 2021, then dropped by 6.01% to $2.1 billion in 2022, then climbed by 13.68% to $2.4 billion in 2023, then grew by 7.18% to $2.5 billion in 2024.